AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

Office of Prescription Drug Promotion (OPDP) recently sent an Untitled Letter to AbbVie, Inc., regarding a television ad starring Serena Williams for its migraine medicine Ubrelvy. According to the ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

On Friday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $194.79 which represents a slight increase of $2.89 or 1.51% from the prior close of $191.9. The stock opened at $192.6 and ...

AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

AbbVie faces growth challenges with mixed Q2 results. Click here for a full investment analysis of ABBV stock.

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...

AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...